AbbVie‘s (ABBV) two-decade Humira monopoly came to an end Tuesday after Amgen (AMGN) launched its biosimilar knockoff at a 55% discount to the original. But AbbVie stock advanced. X The biosimil...
Tag: AbbVie
AbbVie cuts earnings forecast due to milestone payments
AbbVie Inc. executives lowered their outlook for the quarter and year in a filing with the Securities and Exchange Commission late Friday, which cited research and development expenses and milestone p...
AbbVie Stock Briefly Breaks Out On A New $30 Million Cancer Deal
AbbVie (ABBV) stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome (IMNM) in antibody development. X Immunome will use its platform to discover up to ...
AbbVie Holds Up in Ailing Market After FDA Approval; Top Funds Buy Shares
Boosted by another approval from the Food and Drug Administration (FDA), AbbVie (ABBV) has its sights set on a new buy point. And top money managers have their eyes on ABBV stock, which made the lates...
Top Dividend Stocks: Leading Biotech AbbVie Hikes Payout
IBD’s Income Investor column highlights top dividend stocks. With a long track record of dividend increases, AbbVie (ABBV) is in focus, generating a strong yield with stable fundamentals. X Biop...
AbbVie Stock Slips as Sales Miss Expectations And Bigger Challenges Await.
Stock in AbbVie slipped after the drug company reported a higher profit than expected, while sales fell short. The revenue shortfall may have reminded investors of a challenge AbbVie (ticker: ABBV) fa...
AbbVie Stock Skids On Mixed Earnings Report, Narrowed 2022 Earnings View
AbbVie stock skidded Friday after “temporary economic headwinds” hamstrung its aesthetics drugs, including face-filler Botox, during the third quarter. X Overall, AbbVie‘s (ABBV) med...
AbbVie Reports Mixed Earnings, Tightens Guidance, Lifts Quarterly Dividend
AbbVie Inc (NYSE: ABBV) reported Q3 adjusted EPS of $3.66, up 29.3% Y/Y and beating the consensus of $3.59. Overall sales increased 3.3% Y/Y (5.4% on an operational basis) to $14.81 billion, missing t...
Top trending stocks after hours: Costco, Ford, Abbvie
Costco (COST): Total comparable store sales rose 8.5% in September, beating Wall Street’s earnings estimate of 6.3% growth. Comparable sales excluding the impacts from changes in gasoline prices and f...
Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360—Here Are The Major U.S. Layoffs This Summer
California pharmaceutical companies AbbVie and Bristol Myers Squibb reportedly plan to cut 360 employees—becoming the latest U.S. companies to reassess their headcounts as employers fear the economy c...
Bristol-Myers versus AbbVie stock: Expert picks a side
AbbVie Inc (NYSE: ABBV) is a better long-term investment than peer Bristol-Myers Squibb Co (NYSE: BMY) even though the latter just secured FDA approval for its Psoriasis pill, says Mohit Bansal. He’s ...
Ups & Downs: Top Pharmaceutical Stocks Post-COVID
Who will be Big Pharma’s winners post-COVID? Getty Images There’s little argument that the COVID-19 pandemic reshaped the world. While families and governments continue to grapple with Omicron v...
Weighed Down by Opioid Litigation, Endo International Files for Bankruptcy
Text size Dreamstime The generic drugmaker Endo International , which faces thousands of lawsuits related to its alleged role in the opioid crisis, filed for bankruptcy late Tuesday morning, while ann...
AbbVie Stock: AbbVie Leans On Immunology Drugs As Covid Slams Aesthetics
AbbVie (ABBV) leaned heavily on immunology drugs in the second quarter, helping offset declines for its biggest blood cancer medicine and several aesthetic treatments. But AbbVie stock fell early Frid...
AbbVie Stock Slips After Earnings, Charge for Potential Opioid Deal
Text size AbbVie said it continues to expect adjusted diluted earnings of between $13.78 and $13.98 per share for the full fiscal year. Dreamstime The drugmaker AbbVie turned in quarterly earnings tha...
AbbVie Stock Crumbles On Mixed Earnings, Slashes 2022 Earnings Outlook
AbbVie stock crumbled Friday after the drugmaker slashed its 2022 earnings outlook after taking an unexpected hit during the first quarter. X The company said it incurred an 8-cent per-share charge in...
Powell’s Plan To Exorcise Inflation Echoes Early 1980s Volcker Crusade
With few exceptions, stocks last week were savaged in the wake of comments made by Federal Reserve Chairman Jerome Powell that all but assured a half-point rate hike at the Federal Open Market Committ...
AbbVie Stock, And Two Other Drug Stocks, Could Reinvigorate — Or Crumble
A bullish first-quarter report could reinvigorate AbbVie stock, an analyst said Thursday after a C-suite setback this week sent shares tumbling. X Mizuho Securities analyst Vamil Divan expects AbbVie ...
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship
AbbVie stock crumbled Wednesday after the company announced President and Vice Chairman Michael Severino will depart at the end of May. X Severino is heading to Flagship Pioneering, the biotech creato...
We Have a New AbbVie Price Target After Our Previous One Was Reached
AbbVie (ABBV) is a research-based biopharmaceutical company that was spun off from Abbott Laboratories (ABT) a number of years ago. Its blockbuster drug Humira brought in billions. We reviewed the cha...
Buy Eli Lilly Stock. Its Obesity Drug Mounjaro Will Be a Hit, Analyst Says.
Text size Eli Lily said in August that initial demand for Mounjaro was strong. Daniel Acker/Bloomberg Eli Lilly’s novel treatment for diabetes and obesity could become one of history’s bestselling dru...